

# Lars Tanum, DMSci

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9096877/publications.pdf>

Version: 2024-02-01

22  
papers

613  
citations

840776

11  
h-index

677142

22  
g-index

22  
all docs

22  
docs citations

22  
times ranked

886  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence. <i>JAMA Psychiatry</i> , 2017, 74, 1197.	11.0	200
2	Evidence of both systemic inflammation and neuroinflammation in fibromyalgia patients, as assessed by a multiplex protein panel applied to the cerebrospinal fluid and to plasma. <i>Journal of Pain Research</i> , 2017, Volume 10, 515-525.	2.0	164
3	Anxiety, Depression, and Insomnia Among Adults With Opioid Dependence Treated With Extended-Release Naltrexone vs Buprenorphine-Naloxone. <i>JAMA Psychiatry</i> , 2019, 76, 127.	11.0	44
4	Clinical efficacy of formula-based bifrontal versus right unilateral electroconvulsive therapy (ECT) in the treatment of major depression among elderly patients: A pragmatic, randomized, assessor-blinded, controlled trial. <i>Journal of Affective Disorders</i> , 2015, 175, 8-17.	4.1	40
5	Effectiveness, safety and feasibility of extended-release naltrexone for opioid dependence: a 9-month follow-up to a 3-month randomized trial. <i>Addiction</i> , 2018, 113, 1840-1849.	3.3	20
6	Design of a randomized controlled trial of extended-release naltrexone versus daily buprenorphine-naloxone for opioid dependence in Norway (NTX-SBX). <i>BMC Pharmacology &amp; Toxicology</i> , 2016, 17, 18.	2.4	18
7	Systematic analysis of the cerebrospinal fluid proteome of fibromyalgia patients. <i>Journal of Proteomics</i> , 2019, 190, 35-43.	2.4	17
8	No increased pain among opioid-dependent individuals treated with extended-release naltrexone or buprenorphine-naloxone: A 3-month randomized study and 9-month open-treatment follow-up study. <i>American Journal on Addictions</i> , 2019, 28, 77-85.	1.4	16
9	Baseline cognitive function does not predict the treatment outcome of electroconvulsive therapy (ECT) in late-life depression. <i>Journal of Affective Disorders</i> , 2015, 185, 67-75.	4.1	13
10	Practitioners' positive attitudes promote shared decision-making in mental health care. <i>Journal of Evaluation in Clinical Practice</i> , 2019, 25, 1041-1049.	1.8	12
11	Speed of recovery from disorientation may predict the treatment outcome of electroconvulsive therapy (ECT) in elderly patients with major depression. <i>Journal of Affective Disorders</i> , 2016, 190, 178-186.	4.1	11
12	&lt;p&gt;CSF levels of apolipoprotein C1 and autotaxin found to associate with neuropathic pain and fibromyalgia&lt;/p&gt;. <i>Journal of Pain Research</i> , 2019, Volume 12, 2875-2889.	2.0	8
13	The Antipsychotic Medication Management Fidelity Scale: Psychometric properties. <i>Administration and Policy in Mental Health and Mental Health Services Research</i> , 2020, 47, 911-919.	2.1	8
14	Availability of Extended-Release Naltrexone May Increase the Number of Opioid-Dependent Individuals in Treatment: Extension of a Randomized Clinical Trial. <i>European Addiction Research</i> , 2019, 25, 303-309.	2.4	7
15	Levels of Impulsivity, Hyperactivity, and Inattention and the Association with Mental Health and Substance Use Severity in Opioid-Dependent Patients Seeking Treatment with Extended-Release Naltrexone. <i>Journal of Clinical Medicine</i> , 2021, 10, 4558.	2.4	7
16	â€˜Not at all what I had expectedâ€™: Discontinuing treatment with extended-release naltrexone (XR-NTX): A qualitative study. <i>Journal of Substance Abuse Treatment</i> , 2021, , 108667.	2.8	7
17	Chronic Pain Among Patients With an Opioid Use Disorder. <i>American Journal on Addictions</i> , 2021, 30, 366-375.	1.4	6
18	Enabling patients to cope with psychotropic medication in mental health care. <i>Medicine (United Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 6</i>	1.0	5

#	ARTICLE	IF	CITATIONS
19	Adapting treatment length to opioid-dependent individuals'™ needs and preferences: a 2-year follow-up to a 1-year study of extended-release naltrexone. <i>Addiction</i> , 2021, 116, 2084.	3.3	5
20	The Predictive Value of Degree of Preference for Extended-Release Naltrexone for Treatment Adherence, Opioid Use, and Relapse. <i>European Addiction Research</i> , 2022, 28, 56-67.	2.4	3
21	Treatment in Nursing Home versus Hospital for Patients with Behavioral and Psychological Symptoms of Dementia. <i>GeroPsych: the Journal of Gerontopsychology and Geriatric Psychiatry</i> , 2012, 25, 97-102.	0.5	1
22	Life satisfaction among individuals with opioid use disorder receiving extended-release naltrexone: A 12-week randomized controlled trial and a 36-week follow-up. <i>Journal of Substance Abuse Treatment</i> , 2022, 135, 108656.	2.8	1